Farren Timothy W, Sadanand Kaushik S, Agrawal Samir G
Department of Haemato-Oncology and Immunophenotyping (SIHMDS), Barts Health NHS Trust, London, United Kingdom.
Immunobiology, Blizard Institute, Queen Mary University of London, London, United Kingdom.
Front Oncol. 2020 Dec 3;10:597730. doi: 10.3389/fonc.2020.597730. eCollection 2020.
Undetectable minimal residual disease (MRD) in Chronic Lymphocytic Leukemia (CLL) has a favorable prognostic outcome compared with MRD that can be detected. This study investigated a flow cytometric assay (CD160-ROR1FCA) targeting the tumor-specific antigens CD160 and receptor tyrosine kinase-like orphan receptor 1 (ROR1), along with CD2, CD5, CD19, CD45. CD160-ROR1FCA was compared with the originally published 8-colour European Research Initiative for CLL (ERIC) gold-standard assay for CLL MRD detection. CD160-ROR1FCA had a limit of detection of 0.001% and showed strong correlation with ERIC ( = 0.98, p < 0.01) with negligible differences in MRD detection (bias -0.3152 95%CI 5.586 to -6.216). Using CD160-ROR1FCA, increased expression of both CD160 and ROR1 was found in Monoclonal B cell Lymphocytosis (MBL) compared to low-level polyclonal B-cell expansions (p < 0.01). Patients in CR and with undetectable MRD had a longer EFS (not reached) than those in CR but with detectable MRD (756 days, p < 0.01) versus 113 days in patients with partial remission (p < 0.01). Patients with MRD levels of >0.01 to 0.1% had a longer EFS (2,333 days), versus levels between 0.1 to 1% (1,049 days). CD160-ROR1FCA is a novel assay for routine CLL MRD measurement and for MBL detection. MRD status assessed by CD160-ROR1FCA after CLL treatment correlated with EFS.
与可检测到的微小残留病（MRD）相比，慢性淋巴细胞白血病（CLL）中无法检测到的MRD具有良好的预后结果。本研究调查了一种针对肿瘤特异性抗原CD160和受体酪氨酸激酶样孤儿受体1（ROR1）以及CD2、CD5、CD19、CD45的流式细胞术检测方法（CD160-ROR1FCA）。将CD160-ROR1FCA与最初发表的用于CLL MRD检测的8色欧洲CLL研究倡议（ERIC）金标准检测方法进行了比较。CD160-ROR1FCA的检测限为0.001%，与ERIC显示出强相关性（ = 0.98，p < 0.01），在MRD检测方面差异可忽略不计（偏差 -0.3152，95%CI为5.586至 -6.216）。使用CD160-ROR1FCA发现，与低水平多克隆B细胞扩增相比，单克隆B细胞淋巴细胞增多症（MBL）中CD160和ROR1的表达均增加（p < 0.01）。完全缓解（CR）且MRD无法检测到的患者的无进展生存期（EFS）（未达到）比CR但MRD可检测到的患者更长（756天，p < 0.01），而部分缓解患者的EFS为113天（p < 0.01）。MRD水平>0.01%至0.1%的患者的EFS更长（2333天），而水平在0.1%至1%之间的患者为1049天。CD160-ROR1FCA是一种用于常规CLL MRD测量和MBL检测的新型检测方法。CLL治疗后通过CD160-ROR1FCA评估的MRD状态与EFS相关。
